Top Markets
#1 Nesa Nesa +816.77%
#2 Cortex Cortex +68.49%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.50%
#4 QuantixAI QuantixAI +23.90%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +19.70%
#7 Pons Pons +18.22%
#8 Instadapp Instadapp +16.92%
#9 Magma Finance Magma Finance +12.52%
#10 OpenEden OpenEden +11.84%
Coin of the day
Nesa Nesa
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Surrozen, Inc. Surrozen, Inc.

Surrozen, Inc.

SRZN
Rang în acțiuni #19466
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Preț acțiune
$21.57
Ultima sincronizare: 2026-07-31
Capitalizare de piață
$161.29M
Schimbare (1 zi)
3.55%
Schimbare (1 an)
94.32%
Țară
US
Tranzacționează Surrozen, Inc. (SRZN)

Categorie

Healthcare
EPS pentru Surrozen, Inc. (SRZN)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Surrozen, Inc., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru Surrozen, Inc. din 2026 până în 2026
EPS la sfârșitul fiecărui an
An EPS Schimbă
Nu sunt suficiente date pentru perioada selectată.
EPS pentru companii similare sau concurente
Companie EPS Diferență EPS Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH